Tumours display an astonishing variation in the spatial distribution, composition and
activation state of immune cells, which impacts their progression and response to …

Myeloid cells are the most abundant immune components of the tumour microenvironment,
where they have a variety of functions, ranging from immunosuppressive to …

The balance of programmed death-1 (PD-1)-expressing CD8+ T cells and regulatory T
(Treg) cells in the tumor microenvironment (TME) determines the clinical efficacy of PD-1 …

With the broad application of cancer immunotherapies such as immune checkpoint inhibitors
in multiple cancer types, the immunological landscape in the tumor microenvironment (TME) …

Lenvatinib is emerging as the first-line therapeutic option for advanced hepatocellular
carcinoma (HCC), but drug resistance remains a major hurdle for its long-term therapy …

Cancer immunotherapy has made remarkable progress in the past decade. Bispecific
antibodies (BsAbs) have acquired much attention as the next generation strategy of antibody …

Traditional cancer chemotherapy easily produces serious toxic and side effects due to the
lack of specific selection of tumor cells, which restricts its curative effect. Targeted delivery …

Purpose: Although the efficacy of programmed cell death–1 (PD-1) blockade is generally
poor for non–small cell lung cancer (NSCLC) with activating mutations of the epidermal …

Immune checkpoint blockade (ICB) therapy has evolved as a revolutionized therapeutic
modality to eradicate tumor cells by releasing the brake of the antitumor immune response …

The genetic circuits that allow cancer cells to evade immune killing via epithelial
mesenchymal plasticity remain poorly understood. Here, we showed that mesenchymal-like …